황반변성·망막

4개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs
AntibodyCurated CoreFDARegeneronApproved

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF

#VEGF-AVEGF-BPIGF#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 244Status Approved
AntibodyCurated CoreFDARocheApproved

ranibizumab (Lucentis, Byooviz, Cimerli)

Wet AMD, DME, RVO, myopic CNV · VEGF-A

#VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 234Status Approved
AntibodyCurated CoreFDARocheApproved

faricimab (Vabysmo, RG7716, faricimab-svoa)

Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion · Ang-2 / VEGF-A

#Ang-2VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 53Status Approved
CGTAAVCurated CoreFDASpark TherapeuticsApproved

voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl)

Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)

#RPE65AAV2#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 7Status Approved